Alaunos Therapeutics, Inc. Board of Directors

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

Mr. Michael Wong

Mr. Michael Wong

Vice President of Finance & Principal Accounting Officer

Mr. Dale Curtis Hogue Jr.

Mr. Dale Curtis Hogue Jr.

Interim CEO & Director

Ms. Melinda Lackey

Ms. Melinda Lackey

Senior VP of Legal, Administration & Secretary

Comments